Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

The Lancet Oncology

Volumn 17, Issue 4, 2016, Pages 452-463

  Kim, Dong Wan ^a   Mehra, Ranee ^b   Tan, Daniel S W ^c   Felip, Enriqueta ^d   Chow, Laura Q M ^e   Camidge, D Ross ^f   Vansteenkiste, Johan ^g   Sharma, Sunil ^h   De Pas, Tommaso ⁱ   Riely, Gregory J ^j   Solomon, Benjamin J ^k   Wolf, Jürgen ^l   Thomas, Michael ^m   Schuler, Martin ⁿ   Liu, Geoffrey ^o   Santoro, Armando ^p   Sutradhar, Santosh ^q   Li, Siyu ^q   Szczudlo, Tomasz ^q   Yovine, Alejandro ^q   Shaw, Alice T ^r   more..

^a Seoul National University Hospital   (South Korea)

^b FOX CHASE CANCER CENTER   (United States)

^c National Cancer Center   (Singapore)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h UNIVERSITY OF UTAH   (United States)

ⁱ EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k PETER MACCALLUM CANCER CENTRE   (Australia)

^l UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^m UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

ⁿ UNIVERSITY HOSPITAL ESSEN   (Germany)

^o PRINCESS MARGARET HOSPITAL   (Canada)

^p HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^q NOVARTIS PHARMA AG   (Switzerland)

^r MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMYLASE; ANAPLASTIC LYMPHOMA KINASE; ASPARTATE AMINOTRANSFERASE; CERITINIB; CREATININE; GAMMA GLUTAMYLTRANSFERASE; TRIACYLGLYCEROL LIPASE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; SULFONE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BRAIN METASTASIS; CANCER CONTROL; CONSTIPATION; CONVULSION; COUGHING; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG RESPONSE; DRUG SAFETY; DYSPEPSIA; DYSPNEA; EUROPE; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; NAUSEA; NON SMALL CELL LUNG CANCER; NORTH AMERICA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RECOMMENDED DRUG DOSE; RESPIRATORY FAILURE; SIDE EFFECT; THORAX PAIN; UNIVERSITY HOSPITAL; VERY ELDERLY; VOMITING; WEIGHT REDUCTION; BLOOD BRAIN BARRIER; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; GENE REARRANGEMENT; GENETICS; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; BLOOD-BRAIN BARRIER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE REARRANGEMENT; HUMANS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SULFONES;

EID: 84960194194     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00614-2     Document Type: Article

References (35)

1. 1 Kwak, EL, Bang, YJ, Camidge, DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363 (2010), 1693–1703.
2. 2 Song, Z, Wang, M, Zhang, A, Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance. Acta Pharm Sin B 5 (2015), 34–37.
3. 3 Chustecka, Z, Ceritinib (Zykadia) recommended for approval in EU. http://www.medscape.com/viewarticle/840585 (accessed May 20, 2015).
4. 4 Malik, SM, Maher, VE, Bijwaard, KE, et al. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Clin Cancer Res 20 (2014), 2029–2034.
5. 5 US Food and Drug Administration. Ceritinib. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm395386.htm (accessed July 16, 2014).
6. 6 Shaw, AT, Ou, SH, Bang, YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371 (2014), 1963–1971.
7. 7 Camidge, DR, Bang, Y-J, Kwak, EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 13 (2012), 1011–1019.
8. 8 Shaw, AT, Kim, DW, Nakagawa, K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368 (2013), 2385–2394.
9. 9 Solomon, BJ, Mok, T, Kim, DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371 (2014), 2167–2177.
10. 10 Katayama, R, Shaw, AT, Khan, TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med, 4, 2012, 120ra17.
11. 11 Ou, SH, Janne, PA, Bartlett, CH, et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol 25 (2014), 415–422.
12. 12 Weickhardt, AJ, Scheier, B, Burke, JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 7 (2012), 1807–1814.
13. 13 Costa, DB, Kobayashi, S, Pandya, SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 29 (2011), e443–e445.
14. 14 Metro, G, Lunardi, G, Floridi, P, et al. CSF concentration of crizotinib in two ALK-positive non-small-cell lung cancer patients with CNS metastases deriving clinical benefit from treatment. J Thorac Oncol 10 (2015), e26–e27.
15. 15 Doebele, RC, Pilling, AB, Aisner, DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 18 (2012), 1472–1482.
16. 16 Tanizaki, J, Okamoto, I, Okabe, T, et al. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. Clin Cancer Res 18 (2012), 6219–6226.
17. 17 National Comprehensive Cancer Network. NCCN Guidelines, 2014: non-small cell lung cancer. http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf (accessed Aug 14, 2014).
18. 18 Shaw, AT, Kim, DW, Mehra, R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 370 (2014), 1189–1197.
19. 19 Friboulet, L, Li, N, Katayama, R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 4 (2014), 662–673.
20. 20 Novartis. Zykadia prescribing information, 2014, Novartis, Basel.
21. 21 Gadgeel, SM, Gandhi, L, Riely, GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 15 (2014), 1119–1128.
22. 22 Nguyen, KS, Kobayashi, S, Costa, DB, Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 10 (2009), 281–289.
23. 23 Pao, W, Miller, VA, Politi, KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med, 2, 2005, e73.
24. 24 Scagliotti, GV, Parikh, P, von Pawel, J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26 (2008), 3543–3551.
25. 25 Kris, MG, Johnson, BE, Berry, LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311 (2014), 1998–2006.
26. 26 Rangachari, D, Yamaguchi, N, VanderLaan, PA, et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer 88 (2015), 108–111.
27. 27 Mok, T, Kim, D-W, Wu, YL, et al. First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). Proc Am Soc Clin Oncol, 32(suppl), 2014, 8002 (abstr).
28. 28 Costa, DB, Shaw, AT, Ou, SH, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 33 (2015), 1881–1888.
29. 29 Fokas, E, Steinbach, JP, Rodel, C, Biology of brain metastases and novel targeted therapies: time to translate the research. Biochim Biophys Acta 1835 (2013), 61–75.
30. 30 Khan, AJ, Dicker, AP, On the merits and limitations of whole-brain radiation therapy. J Clin Oncol 31 (2013), 11–13.
31. 31 Lukas, RV, Lesniak, MS, Salgia, R, Brain metastases in non-small-cell lung cancer: better outcomes through current therapies and utilization of molecularly targeted approaches. CNS Oncol 3 (2014), 61–75.
32. 32 Kerstein, D, Gettinger, S, Gold, K, et al. Evaluation of anaplastic lymphoma kinase (ALK) inhibitor brigatinib [AP26113] in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) and brain metastases. Ann Oncol 26:suppl 1 (2015), i60–i61 (abstr).
33. 33 Rothenstein, JM, Letarte, N, Managing treatment-related adverse events associated with Alk inhibitors. Curr Oncol 21 (2014), 19–26.
34. 34 Mok, T, Spigel, D, Felip, E, et al. ASCEND-2: a single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). Proc Am Soc Clin Oncol, 33(suppl), 2015, 8059 (abstr).
35. 35 Felip, E, Orlov, S, Park, K, et al. ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALK inhibitor-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol, 33(suppl), 2015, 8060 (abstr).